Psilocybin Microdosing — The Evidence Does Not Hold Up
By Duncan Krostue - 13/09/2026 - 0 comments
I have covered psilocybin research before on this blog — specifically how full-dose experiences create measurable changes in brain network integration. So when a new systematic review on microdosing landed in Frontiers in Psychiatry, I paid attention. The question is simple: does taking tiny amounts of psilocybin regularly actually do anything?
The review, published September 2026, screened 897 references across every major database and ended up with 11 studies covering 3,262 participants. Most were male (70%), and demographic data was spotty. And here is the problem: five of those 11 studies were single-patient case reports or small case series. Only two were placebo-controlled trials, and neither showed significant improvement from microdosing.
"The two placebo-controlled trials have not shown significant improvements."
People report better mood, more creativity, improved focus, enhanced social connection — the subjective benefits are there in the qualitative data. But when you control for expectation, the signal disappears. One study even found control groups outperformed the microdosing group on some outcomes.
Most microdosing motivations — 86% — were non-medical. People wanted cognitive enhancement, creativity, productivity. Only 14% related to medical diagnoses. And while adverse events were rarely tracked systematically, one study did report psychosis-like experiences, suicidal ideation, and panic attacks at the higher end of microdosing doses.
"Most data are qualitative or cross-sectional, with five studies consisting of single-patient case reports or small case series."
The review is careful to say current evidence is insufficient to determine efficacy or safety, which is researcher-speak for "we still do not know if this works." Given how popular microdosing has become — especially in tech and creative circles — that should give anyone pause before self-experimenting. The placebo is strong. The data is weak. Proceed accordingly.
"The two placebo-controlled trials have not shown significant improvements." — Frontiers in Psychiatry systematic review "Most data are qualitative or cross-sectional, with five studies consisting of single-patient case reports or small case series." — Frontiers in Psychiatry systematic review "The review stressed that evidence from supervised, perceptible-dose therapy cannot be assumed to apply to modern microdosing." — News-Medical